These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071 [TBL] [Abstract][Full Text] [Related]
29. Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis. Bojesen KB; Ebdrup BH; Jessen K; Sigvard A; Tangmose K; Edden RAE; Larsson HBW; Rostrup E; Broberg BV; Glenthøj BY Psychol Med; 2020 Oct; 50(13):2182-2193. PubMed ID: 31524118 [TBL] [Abstract][Full Text] [Related]
30. The Use of Cannabis as a Predictor of Early Onset of Bipolar Disorder and Suicide Attempts. Leite RT; Nogueira Sde O; do Nascimento JP; de Lima LS; da Nóbrega TB; Virgínio Mda S; Moreno LM; Sampaio BH; de Matos E Souza FG Neural Plast; 2015; 2015():434127. PubMed ID: 26097750 [TBL] [Abstract][Full Text] [Related]
31. Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety. Laprevote V; Schwan R; Schwitzer T; Rolland B; Thome J Curr Pharm Des; 2015; 21(23):3298-305. PubMed ID: 26088109 [TBL] [Abstract][Full Text] [Related]
32. Trends in cannabis use disorder by cigarette smoking status in the United States, 2002-2016. Weinberger AH; Pacek LR; Wall MM; Zvolensky MJ; Copeland J; Galea S; Nahvi S; Moeller SJ; Hasin DS; Goodwin RD Drug Alcohol Depend; 2018 Oct; 191():45-51. PubMed ID: 30077055 [TBL] [Abstract][Full Text] [Related]
33. Influence of pregabalin maintenance on cannabis effects and related behaviors in daily cannabis users. Lile JA; Alcorn JL; Hays LR; Kelly TH; Stoops WW; Wesley MJ; Westgate PM Exp Clin Psychopharmacol; 2022 Oct; 30(5):560-574. PubMed ID: 33983765 [TBL] [Abstract][Full Text] [Related]
34. Lower dACC glutamate in cannabis users during early phase abstinence. Zuo CS; Davis KA; Lukas SE Neuropsychopharmacology; 2022 Oct; 47(11):1969-1975. PubMed ID: 35484401 [TBL] [Abstract][Full Text] [Related]
36. N-acetylcysteine does not alter neurometabolite levels in non-treatment seeking adolescents who use alcohol heavily: A preliminary randomized clinical trial. Kirkland AE; Browning BD; Green R; Liu H; Maralit AM; Ferguson PL; Meyerhoff DJ; Prisciandaro JJ; Miranda R; Brady KT; Tomko RL; Gray KM; Squeglia LM Neuropsychopharmacology; 2023 Jul; 48(8):1184-1193. PubMed ID: 36878996 [TBL] [Abstract][Full Text] [Related]
37. The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine. Tomko RL; Gilmore AK; Gray KM Addict Behav; 2018 Oct; 85():26-30. PubMed ID: 29803870 [TBL] [Abstract][Full Text] [Related]
38. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. Levin FR; Mariani JJ; Pavlicova M; Brooks D; Glass A; Mahony A; Nunes EV; Bisaga A; Dakwar E; Carpenter KM; Sullivan MA; Choi JC Drug Alcohol Depend; 2016 Feb; 159():53-60. PubMed ID: 26711160 [TBL] [Abstract][Full Text] [Related]
39. Cigarette smoking and its relationship to mood disorder symptoms and co-occurring alcohol and cannabis use disorders following first hospitalization for bipolar disorder. Heffner JL; DelBello MP; Anthenelli RM; Fleck DE; Adler CM; Strakowski SM Bipolar Disord; 2012 Feb; 14(1):99-108. PubMed ID: 22329477 [TBL] [Abstract][Full Text] [Related]
40. Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. McRae-Clark AL; Gray KM; Baker NL; Sherman BJ; Squeglia L; Sahlem GL; Wagner A; Tomko R Drug Alcohol Depend; 2021 Dec; 229(Pt B):109111. PubMed ID: 34655945 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]